smscall
logo
Pharma & Healthcare

Published On: Feb 6, 2025

Global Adult Preventable Vaccines Market Outlook and Growth Opportunities 2025

  • starstarstarstarstar
  • 0
  • 0 Reviews
  • 197 Pages
  • 0 Views

Version Type

$4,250.00

Summary
According to APO Research, the global Adult Preventable Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Adult Preventable Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Adult Preventable Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Adult Preventable Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Adult Preventable Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Adult Preventable Vaccines market include Sanofi Pasteur, Johnson & Johnson (Janssen), Pfizer Inc., GlaxoSmithKline plc (GSK), Sinovac Biotech, Sinopharm Group Co.,, Serum Institute of India Pvt., Novavax, Inc. and Moderna, Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Adult Preventable Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Adult Preventable Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Adult Preventable Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Adult Preventable Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Adult Preventable Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Adult Preventable Vaccines sales, projected growth trends, production technology, application and end-user industry.
Adult Preventable Vaccines Segment by Company
Sanofi Pasteur
Johnson & Johnson (Janssen)
Pfizer Inc.
GlaxoSmithKline plc (GSK)
Sinovac Biotech
Sinopharm Group Co.,
Serum Institute of India Pvt.
Novavax, Inc.
Moderna, Inc.
Merck & Co., Inc.
Emergent BioSolutions Inc.
Daiichi Sankyo Company
CSL Limited (Seqirus)
Bharat Biotech International
AstraZeneca plc
Adult Preventable Vaccines Segment by Type
Viral Vector Vaccines
Peptide Vaccines
Inactivated Vaccines
Subunit Vaccines
Mrna Vaccines
Adult Preventable Vaccines Segment by Application
Prevent Herpes Zoster
Prevent Pneumococcal Infection
Prevent Influenza
Prevent Human Papillomavirus (Hpv)
Prevent Hepatitis B
Other
Adult Preventable Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Adult Preventable Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Adult Preventable Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Adult Preventable Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Adult Preventable Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adult Preventable Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Adult Preventable Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adult Preventable Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Adult Preventable Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Adult Preventable Vaccines industry.
Chapter 3: Detailed analysis of Adult Preventable Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Adult Preventable Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Adult Preventable Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Table 1:Adult Preventable Vaccines Industry Trends
Table 2:Adult Preventable Vaccines Industry Drivers
Table 3:Adult Preventable Vaccines Industry Opportunities and Challenges
Table 4:Adult Preventable Vaccines Industry Restraints
Table 5:Global Adult Preventable Vaccines Revenue by Company (US$ Million) & (2020-2025)
Table 6:Global Adult Preventable Vaccines Revenue Share by Company (2020-2025)
Table 7:Global Adult Preventable Vaccines Sales Volume by Company (K Units) & (2020-2025)
Table 8:Global Adult Preventable Vaccines Sales Volume Share by Company (2020-2025)
Table 9:Global Adult Preventable Vaccines Average Price (US$/Unit) of Company (2020-2025)
Table 10:Global Adult Preventable Vaccines Company Ranking, (2023-2025) & (USD Million)
Table 11:Global Adult Preventable Vaccines Key Company Manufacturing Base & Headquarters
Table 12:Global Adult Preventable Vaccines Company, Product Type & Application
Table 13:Global Adult Preventable Vaccines Company Establishment Date
Table 14:Global Company Market Concentration Ratio (CR5 and HHI)
Table 15:Global Adult Preventable Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2024)
Table 16:Mergers & Acquisitions, Expansion
Table 17:Significant Companies of Viral Vector Vaccines
Table 18:Significant Companies of Peptide Vaccines
Table 19:Significant Companies of Inactivated Vaccines
Table 20:Significant Companies of Subunit Vaccines
Table 21:Significant Companies of Mrna Vaccines
Table 22:Global Adult Preventable Vaccines Sales Volume by Type 2020 VS 2024 VS 2031 (K Units)
Table 23:Global Adult Preventable Vaccines Sales Volume by Type (2020-2025) & (K Units)
Table 24:Global Adult Preventable Vaccines Sales Volume by Type (2026-2031) & (K Units)
Table 25:Global Adult Preventable Vaccines Sales Volume Share by Type (2020-2025)
Table 26:Global Adult Preventable Vaccines Sales Volume Share by Type (2026-2031)
Table 27:Global Adult Preventable Vaccines Sales Value by Type 2020 VS 2024 VS 2031 (US$ Million)
Table 28:Global Adult Preventable Vaccines Sales Value by Type (2020-2025) & (US$ Million)
Table 29:Global Adult Preventable Vaccines Sales Value by Type (2026-2031) & (US$ Million)
Table 30:Global Adult Preventable Vaccines Sales Value Share by Type (2020-2025)
Table 31:Global Adult Preventable Vaccines Sales Value Share by Type (2026-2031)
Table 32:Significant Companies of Prevent Herpes Zoster
Table 33:Significant Companies of Prevent Pneumococcal Infection
Table 34:Significant Companies of Prevent Influenza
Table 35:Significant Companies of Prevent Human Papillomavirus (Hpv)
Table 36:Significant Companies of Prevent Hepatitis B
Table 37:Significant Companies of Other
Table 38:Global Adult Preventable Vaccines Sales Volume by Application 2020 VS 2024 VS 2031 (K Units)
Table 39:Global Adult Preventable Vaccines Sales Volume by Application (2020-2025) & (K Units)
Table 40:Global Adult Preventable Vaccines Sales Volume by Application (2026-2031) & (K Units)
Table 41:Global Adult Preventable Vaccines Sales Volume Share by Application (2020-2025)
Table 42:Global Adult Preventable Vaccines Sales Volume Share by Application (2026-2031)
Table 43:Global Adult Preventable Vaccines Sales Value by Application 2020 VS 2024 VS 2031 (US$ Million)
Table 44:Global Adult Preventable Vaccines Sales Value by Application (2020-2025) & (US$ Million)
Table 45:Global Adult Preventable Vaccines Sales Value by Application (2026-2031) & (US$ Million)
Table 46:Global Adult Preventable Vaccines Sales Value Share by Application (2020-2025)
Table 47:Global Adult Preventable Vaccines Sales Value Share by Application (2026-2031)
Table 48:Global Adult Preventable Vaccines Sales by Region: 2020 VS 2024 VS 2031 (K Units)
Table 49:Global Adult Preventable Vaccines Sales by Region (2020-2025) & (K Units)
Table 50:Global Adult Preventable Vaccines Sales Market Share by Region (2020-2025)
Table 51:Global Adult Preventable Vaccines Sales by Region (2026-2031) & (K Units)
Table 52:Global Adult Preventable Vaccines Sales Market Share by Region (2026-2031)
Table 53:Global Adult Preventable Vaccines Sales Value Comparison by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 54:Global Adult Preventable Vaccines Sales Value by Region (2020-2025) & (US$ Million)
Table 55:Global Adult Preventable Vaccines Sales Value Share by Region (2020-2025)
Table 56:Global Adult Preventable Vaccines Sales Value by Region (2026-2031) & (US$ Million)
Table 57:Global Adult Preventable Vaccines Sales Value Share by Region (2026-2031)
Table 58:Global Adult Preventable Vaccines Market Average Price (US$/Unit) by Region (2020-2025)
Table 59:Global Adult Preventable Vaccines Market Average Price (US$/Unit) by Region (2026-2031)
Table 60:Global Adult Preventable Vaccines Sales by Country: 2020 VS 2024 VS 2031 (K Units)
Table 61:Global Adult Preventable Vaccines Sales Value by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 62:Global Adult Preventable Vaccines Sales by Country (2020-2025) & (K Units)
Table 63:Global Adult Preventable Vaccines Sales Market Share by Country (2020-2025)
Table 64:Global Adult Preventable Vaccines Sales by Country (2026-2031) & (K Units)
Table 65:Global Adult Preventable Vaccines Sales Market Share by Country (2026-2031)
Table 66:Global Adult Preventable Vaccines Sales Value by Country (2020-2025) & (US$ Million)
Table 67:Global Adult Preventable Vaccines Sales Value Market Share by Country (2020-2025)
Table 68:Global Adult Preventable Vaccines Sales Value by Country (2026-2031) & (US$ Million)
Table 69:Global Adult Preventable Vaccines Sales Value Market Share by Country (2026-2031)
Table 70:Sanofi Pasteur Company Information
Table 71:Sanofi Pasteur Business Overview
Table 72:Sanofi Pasteur Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73:Sanofi Pasteur Adult Preventable Vaccines Product Portfolio
Table 74:Sanofi Pasteur Recent Development
Table 75:Johnson & Johnson (Janssen) Company Information
Table 76:Johnson & Johnson (Janssen) Business Overview
Table 77:Johnson & Johnson (Janssen) Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78:Johnson & Johnson (Janssen) Adult Preventable Vaccines Product Portfolio
Table 79:Johnson & Johnson (Janssen) Recent Development
Table 80:Pfizer Inc. Company Information
Table 81:Pfizer Inc. Business Overview
Table 82:Pfizer Inc. Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83:Pfizer Inc. Adult Preventable Vaccines Product Portfolio
Table 84:Pfizer Inc. Recent Development
Table 85:GlaxoSmithKline plc (GSK) Company Information
Table 86:GlaxoSmithKline plc (GSK) Business Overview
Table 87:GlaxoSmithKline plc (GSK) Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88:GlaxoSmithKline plc (GSK) Adult Preventable Vaccines Product Portfolio
Table 89:GlaxoSmithKline plc (GSK) Recent Development
Table 90:Sinovac Biotech Company Information
Table 91:Sinovac Biotech Business Overview
Table 92:Sinovac Biotech Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93:Sinovac Biotech Adult Preventable Vaccines Product Portfolio
Table 94:Sinovac Biotech Recent Development
Table 95:Sinopharm Group Co., Company Information
Table 96:Sinopharm Group Co., Business Overview
Table 97:Sinopharm Group Co., Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98:Sinopharm Group Co., Adult Preventable Vaccines Product Portfolio
Table 99:Sinopharm Group Co., Recent Development
Table 100:Serum Institute of India Pvt. Company Information
Table 101:Serum Institute of India Pvt. Business Overview
Table 102:Serum Institute of India Pvt. Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103:Serum Institute of India Pvt. Adult Preventable Vaccines Product Portfolio
Table 104:Serum Institute of India Pvt. Recent Development
Table 105:Novavax, Inc. Company Information
Table 106:Novavax, Inc. Business Overview
Table 107:Novavax, Inc. Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108:Novavax, Inc. Adult Preventable Vaccines Product Portfolio
Table 109:Novavax, Inc. Recent Development
Table 110:Moderna, Inc. Company Information
Table 111:Moderna, Inc. Business Overview
Table 112:Moderna, Inc. Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113:Moderna, Inc. Adult Preventable Vaccines Product Portfolio
Table 114:Moderna, Inc. Recent Development
Table 115:Merck & Co., Inc. Company Information
Table 116:Merck & Co., Inc. Business Overview
Table 117:Merck & Co., Inc. Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118:Merck & Co., Inc. Adult Preventable Vaccines Product Portfolio
Table 119:Merck & Co., Inc. Recent Development
Table 120:Emergent BioSolutions Inc. Company Information
Table 121:Emergent BioSolutions Inc. Business Overview
Table 122:Emergent BioSolutions Inc. Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123:Emergent BioSolutions Inc. Adult Preventable Vaccines Product Portfolio
Table 124:Emergent BioSolutions Inc. Recent Development
Table 125:Daiichi Sankyo Company Company Information
Table 126:Daiichi Sankyo Company Business Overview
Table 127:Daiichi Sankyo Company Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128:Daiichi Sankyo Company Adult Preventable Vaccines Product Portfolio
Table 129:Daiichi Sankyo Company Recent Development
Table 130:CSL Limited (Seqirus) Company Information
Table 131:CSL Limited (Seqirus) Business Overview
Table 132:CSL Limited (Seqirus) Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133:CSL Limited (Seqirus) Adult Preventable Vaccines Product Portfolio
Table 134:CSL Limited (Seqirus) Recent Development
Table 135:Bharat Biotech International Company Information
Table 136:Bharat Biotech International Business Overview
Table 137:Bharat Biotech International Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138:Bharat Biotech International Adult Preventable Vaccines Product Portfolio
Table 139:Bharat Biotech International Recent Development
Table 140:AstraZeneca plc Company Information
Table 141:AstraZeneca plc Business Overview
Table 142:AstraZeneca plc Adult Preventable Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143:AstraZeneca plc Adult Preventable Vaccines Product Portfolio
Table 144:AstraZeneca plc Recent Development
Table 145:Key Raw Materials
Table 146:Raw Materials Key Suppliers
Table 147:Adult Preventable Vaccines Distributors List
Table 148:Adult Preventable Vaccines Customers List
Table 149:Research Programs/Design for This Report
Table 150:Authors List of This Report
Table 151:Secondary Sources
Table 152:Primary Sources
Figure 1:Adult Preventable Vaccines Product Image
Figure 2:Global Adult Preventable Vaccines Sales Value (US$ Million), 2020 VS 2024 VS 2031
Figure 3:Global Adult Preventable Vaccines Sales Value (2020-2031) & (US$ Million)
Figure 4:Global Adult Preventable Vaccines Sales (2020-2031) & (K Units)
Figure 5:Global Adult Preventable Vaccines Sales Average Price (US$/Unit) & (2020-2031)
Figure 6:Global Adult Preventable Vaccines Company Revenue Ranking in 2024 (US$ Million)
Figure 7:Global Top 5 and 10 Company Market Share by Revenue in 2024 (US$ Million)
Figure 8:Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 9:Viral Vector Vaccines Image
Figure 10:Peptide Vaccines Image
Figure 11:Inactivated Vaccines Image
Figure 12:Subunit Vaccines Image
Figure 13:Mrna Vaccines Image
Figure 14:Global Adult Preventable Vaccines Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
Figure 15:Global Adult Preventable Vaccines Sales Volume Share 2020 VS 2024 VS 2031
Figure 16:Global Adult Preventable Vaccines Sales Volume Share by Type (2020-2031)
Figure 17:Global Adult Preventable Vaccines Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 18:Global Adult Preventable Vaccines Sales Value Share 2020 VS 2024 VS 2031
Figure 19:Global Adult Preventable Vaccines Sales Value Share by Type (2020-2031)
Figure 20:Prevent Herpes Zoster Image
Figure 21:Prevent Pneumococcal Infection Image
Figure 22:Prevent Influenza Image
Figure 23:Prevent Human Papillomavirus (Hpv) Image
Figure 24:Prevent Hepatitis B Image
Figure 25:Other Image
Figure 26:Global Adult Preventable Vaccines Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
Figure 27:Global Adult Preventable Vaccines Sales Volume Share 2020 VS 2024 VS 2031
Figure 28:Global Adult Preventable Vaccines Sales Volume Share by Application (2020-2031)
Figure 29:Global Adult Preventable Vaccines Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 30:Global Adult Preventable Vaccines Sales Value Share 2020 VS 2024 VS 2031
Figure 31:Global Adult Preventable Vaccines Sales Value Share by Application (2020-2031)
Figure 32:Global Adult Preventable Vaccines Sales by Region: 2020 VS 2024 VS 2031 (K Units)
Figure 33:Global Adult Preventable Vaccines Sales Market Share by Region: 2020 VS 2024 VS 2031
Figure 34:Global Adult Preventable Vaccines Sales Value Comparison by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 35:Global Adult Preventable Vaccines Sales Value Share by Region: 2020 VS 2024 VS 2031
Figure 36:North America Adult Preventable Vaccines Sales Value (2020-2031) & (US$ Million)
Figure 37:North America Adult Preventable Vaccines Sales Value Share by Country (%), 2024 VS 2031
Figure 38:Europe Adult Preventable Vaccines Sales Value (2020-2031) & (US$ Million)
Figure 39:Europe Adult Preventable Vaccines Sales Value Share by Country (%), 2024 VS 2031
Figure 40:Asia-Pacific Adult Preventable Vaccines Sales Value (2020-2031) & (US$ Million)
Figure 41:Asia-Pacific Adult Preventable Vaccines Sales Value Share by Country (%), 2024 VS 2031
Figure 42:South America Adult Preventable Vaccines Sales Value (2020-2031) & (US$ Million)
Figure 43:South America Adult Preventable Vaccines Sales Value Share by Country (%), 2024 VS 2031
Figure 44:Middle East & Africa Adult Preventable Vaccines Sales Value (2020-2031) & (US$ Million)
Figure 45:Middle East & Africa Adult Preventable Vaccines Sales Value Share by Country (%), 2024 VS 2031
Figure 46:USA Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 47:USA Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 48:USA Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 49:Canada Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 50:Canada Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 51:Canada Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 52:Mexico Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 53:Mexico Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 54:Mexico Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 55:Germany Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 56:Germany Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 57:Germany Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 58:France Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 59:France Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 60:France Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 61:U.K. Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 62:U.K. Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 63:U.K. Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 64:Italy Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 65:Italy Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 66:Italy Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 67:Spain Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 68:Spain Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 69:Spain Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 70:Russia Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 71:Russia Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 72:Russia Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 73:Netherlands Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 74:Netherlands Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 75:Netherlands Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 76:Nordic Countries Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 77:Nordic Countries Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 78:Nordic Countries Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 79:China Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 80:China Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 81:China Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 82:Japan Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 83:Japan Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 84:Japan Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 85:South Korea Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 86:South Korea Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 87:South Korea Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 88:India Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 89:India Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 90:India Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 91:Australia Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 92:Australia Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 93:Australia Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 94:Southeast Asia Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 95:Southeast Asia Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 96:Southeast Asia Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 97:Brazil Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 98:Brazil Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 99:Brazil Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 100:Argentina Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 101:Argentina Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 102:Argentina Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 103:Chile Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 104:Chile Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 105:Chile Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 106:Colombia Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 107:Colombia Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 108:Colombia Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 109:Peru Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 110:Peru Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 111:Peru Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 112:Saudi Arabia Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 113:Saudi Arabia Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 114:Saudi Arabia Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 115:Israel Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 116:Israel Arabia Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 117:Israel Arabia Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 118:UAE Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 119:UAE Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 120:UAE Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 121:Turkey Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 122:Turkey Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 123:Turkey Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 124:Iran Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 125:Iran Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 126:Iran Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 127:Egypt Adult Preventable Vaccines Sales Value Growth Rate (2020-2031) & (US$ Million)
Figure 128:Egypt Adult Preventable Vaccines Sales Value Share by Type, 2024 VS 2031 & (%)
Figure 129:Egypt Adult Preventable Vaccines Sales Value Share by Application, 2024 VS 2031 & (%)
Figure 130:Adult Preventable Vaccines Value Chain
Figure 131:Manufacturing Cost Structure
Figure 132:Adult Preventable Vaccines Sales Mode & Process
Figure 133:Direct Comparison with Distribution Share
Figure 134:Distributors Profiles
Figure 135:Years Considered
Figure 136:Research Process
Figure 137:Key Executives Interviewed

Request a Sample

Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Report Cover

Pharma & Healthcare

Global Adult Preventable Vaccines Market Outlook and Growth Opportunities 2025

0| 0 Reviews

Pages: 197

Complete Your Request

Select Country
Phone

Customer reviews

  • starstarstarstarstar
  • 0 out of 5
  • 0 Reviews

5

star rating

4

star rating

3

star rating

2

star rating

1

star rating

No Rating Review Exist.

Write Review
  • starstarstarstarstar

Suggested Report

View More

No data found.